Rational antibiotic therapy and the position of ampicillin/sulbactam

Lode, H.

doi:10.1016/j.ijantimicag.2008.02.004

Cited by 43 publications

(41 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of this combination is recommended by national and international guidelines as first-line therapy for various respiratory and skin infections (1). In 2003, a survey in 130 hospitals in the United States involving 1,795,504 patients revealed that the ampicillin group of antibiotics seems to be the most commonly prescribed (2).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of Ampicillin/Sulbactam in Critically Ill Patients with Acute Kidney Injury undergoing Extended Dialysis

Lorenzen

Broll

Kaever

et al. 2012

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives The fixed antibacterial combination of ampicillin and sulbactam is frequently used for various infections. Intact kidneys eliminate approximately 71% of ampicillin and 78% of sulbactam. Patients on thrice-weekly low-flux hemodialysis exhibit an ampicillin t 1/2 of 2.3 hours on and 17.4 hours off dialysis. Despite its frequent use in intensive care units, there are no available dosing recommendations for patients with AKI undergoing renal replacement therapy. The aims of this study were to evaluate the pharmacokinetics of ampicillin/ sulbactam in critically ill patients with AKI undergoing extended dialysis (ED) and to establish a dosing recommendation for this treatment method.Design, setting, participants, & measurements Twelve critically ill patients with anuric AKI being treated with ED were enrolled in a prospective, open-label, observational pharmacokinetic study. Pharmacokinetics after a single dose of ampicillin/sulbactam (2 g/1 g) was obtained in 12 patients. Multiple-dose pharmacokinetics after 4 days of twice-daily ampicillin/sulbactam (2 g/1 g) was obtained in three patients. ResultsThe mean dialyzer clearance for ampicillin/sulbactam was 80.167.7/83.3612.1 ml/min. The t 1/2 of ampicillin and sulbactam in patients with AKI undergoing ED were 2.860.8 hours and 3.561.5 hours, respectively. There was no significant accumulation using a twice-daily dosage of 2 g/1 g ampicillin/sulbactam.Conclusions Our data suggest that in patients treated with ED using a high-flux dialyzer (polysulphone, 1.3 m 2 ; blood and dialysate flow, 160 ml/min; treatment time, 480 minutes), a twice-daily dosing schedule of at least 2 g/1 g ampicillin/sulbactam, with one dose given after ED, should be used to avoid underdosing.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of Ampicillin/Sulbactam in Critically Ill Patients with Acute Kidney Injury undergoing Extended Dialysis

Lorenzen

Broll

Kaever

et al. 2012

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Its activity is comparable with that of ampicillin against bacteria, for example S. pneumoniae, that are resistant to beta-lactam antibiotics as a result of mechanisms other than beta-lactamase production. So it provides coverage against the wide variety of possible pathogens of pneumonia in all ages [2]. It has also good activity against carbapenem-resistant Acinetobacter spp.…”

Section: Introductionmentioning

confidence: 99%

Ampicillin/sulbactam for children hospitalized with community-acquired pneumonia

Tapisiz

Özdemir

Çıftçı

et al. 2011

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

“…Furthermore, suboptimal outcomes in a study of ventilator-associated pneumonia (VAP) in trauma patients suggest that ampicillin/sulbactam is associated with decreased susceptibly for common pathogens associated with VAP, although A. baumannii was not among the common pathogens in this study [156]. A list of studies comparing the effectiveness of ampicillin/sulbactam with its comparators were discussed in detail in a review article by Lode [146].…”

Section: Microbiologymentioning

confidence: 86%

“…baumannii towards ampicillin/sulbactam have been documented in several recent surveillance reports, which are of concern [146,158].…”

Section: Microbiologymentioning

confidence: 97%

See 1 more Smart Citation

Improving antimicrobial use in critically ill patients

Adnan¹

View full text Add to dashboard Cite

Rational antibiotic therapy and the position of ampicillin/sulbactam

Cited by 43 publications

References 100 publications

Pharmacokinetics of Ampicillin/Sulbactam in Critically Ill Patients with Acute Kidney Injury undergoing Extended Dialysis

Pharmacokinetics of Ampicillin/Sulbactam in Critically Ill Patients with Acute Kidney Injury undergoing Extended Dialysis

Ampicillin/sulbactam for children hospitalized with community-acquired pneumonia

Improving antimicrobial use in critically ill patients

Contact Info

Product

Resources

About